Burning Rock Biotech Limited Sponsored ADR

BNR Healthcare Diagnostics & Research

Burning Rock Biotech Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $77.2 million, up 9.18% from fiscal 2024. In the quarter to June 2026, revenue fell 4.22%, EPS fell 98.4%, free cash flow grew 46.0% and total debt fell 5.02%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

12.69 2.91 −18.65%
Market cap
$137.1M
P/E
0.0×
Fwd P/E
11.1×
Dividend yield
—
F-score
5/9
Altman Z
−2.95
Beneish M
−2.47
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
Piotroski F-Score
5 5 6 4 — — — — —
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
(2.95) (5.70) (4.58) (1.61) 7.23 25.58 — — —
P/S ratio
2.78 0.98 1.31 2.75 12.46 381.27 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(11.46) (12.40) (9.52) (4.39) 3.10 13.35 — (11.27) —
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Beneish M-Score
(2.47) (2.87) (4.34) (4.17) (1.54) — — — —
P/Operating CF
67.70 21.56 (31.36) (19.46) (54.37) (1,830.84) 0.00 0.00 0.00
P/B ratio
2.80 0.87 0.92 1.34 3.43 64.79 0.00 0.00 0.00
Price to Tangible BV
2.80 0.87 0.92 1.34 3.44 64.89 0.00 0.00 0.00
EV/Sales
1.89 0.01 0.20 1.20 9.60 375.83 0.00 0.00 0.00
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(35.81) (0.04) (0.42) (1.47) (10.21) (8,207.08) 0.00 0.00 0.00
EV/FCF
(8.83) (0.02) (0.17) (1.47) (10.21) (8,207.08) 0.00 0.00 0.00
Quick Ratio
2.63 2.53 2.82 2.52 4.29 9.83 3.78 0.75 —
Current Ratio
2.99 2.92 3.36 3.06 4.89 10.45 4.24 1.03 —
Net Debt/EBITDA
14.48 1.71 1.15 1.02 1.94 5.92 2.48 (0.99) 0.00
Debt/Assets
0.23% 0.00% 0.00% 3.17% 2.27% 1.58% 0.00% 73.06% 0.00%
Debt/Equity
0.00 0.00 0.00 0.04 0.03 0.02 0.11 (37.07) —
Asset Turnover
0.65 0.53 0.40 0.28 0.21 0.29 2.04 1.16 0.00
Operating CF/Net income
0.51 0.27 0.39 0.47 0.60 0.16 0.68 0.64 0.72
Capex/Depreciation
(0.20) (0.08) (0.07) (0.55) (4.46) (2.37) 0.00 0.00 0.00
Interest Coverage
(1,961.00) — — 9,476.33 (519.00) (619.66) (155.72) (19.43) (24.51)
ROE
(10.14%) (50.57%) (66.68%) (61.56%) (37.85%) (59.51%) 44.80% 32.53% 0.00%
ROA
(6.64%) (35.47%) (48.89%) (47.92%) (32.66%) (31.28%) (178.19%) (129.38%) 0.00%
ROIC
(61.14%) (380.90%) (273.06%) (216.16%) (126.40%) (146.67%) 0.00% 0.00% —
Return on Tangible Assets
(10.59%) (62.18%) (86.85%) (88.36%) (44.91%) (19.72%) (54.16%) (309.58%) 0.00%
Average Days of Receivables
114.74 107.57 86.16 71.26 66.26 74.90 197.84 138.87 0.00
Research and Development Expense of Revenue
30.86% 45.03% 64.57% 74.90% 72.43% 61.40% 41.12% 50.41% 44.10%
Selling, General and Administrative Expense of Revenue
53.98% 87.73% 127.56% 166.64% 156.22% 107.56% 74.80% 91.52% 129.12%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
2.57% 30.17% 48.51% 58.02% 55.61% 40.29% 0.00% 0.00% 0.00%
Graham Net Nets
0.30 0.93 0.87 0.54 0.22 0.01 0.00 0.00 0.00
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(2.48%) (21.18%) (91.85%) (63.89%) (12.38%) (1.99%) (1.18%) (1.18%) (1.18%)
Free Cash Flow Yield
(7.71%) (44.36%) (87.69%) (29.51%) (7.55%) (0.01%) 0.00% 0.00% 0.00%
Revenue per Share
7.26 6.87 7.39 7.86 7.65 9.60 0.53 0.30 0.16
Operating CF per Share
(0.38) (1.23) (3.52) (6.37) (7.20) (1.64) (0.32) (0.22) (0.19)
Capex per Share
(0.06) (0.06) (0.13) (0.95) (3.21) (1.76) 0.00 0.00 0.00
Free Cash Flow per Share
(0.44) (1.29) (3.65) (7.32) (10.40) (3.40) (0.32) (0.22) (0.19)
Cash per Share
6.47 6.95 8.46 12.91 22.63 51.07 0.57 0.19 0.00
Shareholders Equity per Share
7.20 7.73 10.57 16.16 27.79 54.06 0.88 (0.01) 0.00
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
7.20 7.73 10.57 16.16 27.79 54.06 0.88 (0.01) 0.00
Free Cash Flow
(4.70) (13.24) (37.33) (76.10) (108.40) (23.36) (33.00) (22.48) (19.78)
Working Capital
70.30 69.91 87.43 122.85 227.34 349.75 76.47 1.21 —
Capital Expenditures
(0.63) (0.60) (1.31) (9.87) (33.40) (12.09) (6.62) (3.74) (3.41)
Net Current Asset Value
64.85 64.68 86.27 120.29 217.76 349.68 69.78 (12.39) —
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.01 0.01 0.02 0.12 0.42 0.18 0.00 0.00 0.00
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.70 1.11 1.01 0.49 0.15 0.30 0.35 0.37 0.00
Cash ROIC
(3.23%) (8.76%) (19.16%) (24.60%) (20.32%) (3.21%) (20.61%) (38.88%) 0.00%
Accounts Receivable Turnover
3.42 3.65 4.48 5.37 5.69 3.03 2.63 1.50 0.00
Accounts Payable Turnover
3.74 5.87 4.94 3.07 2.94 4.93 7.57 5.25 2.75
Inventory Turnover
2.52 2.30 1.71 1.39 1.52 1.89 2.02 3.15 1.65
Average Days of Payables
108.82 80.28 37.84 101.51 160.21 111.67 41.27 77.53 117.46
Days of Inventory on Hand
129.74 148.99 144.60 259.65 312.92 214.07 194.22 233.80 (4.52)
Average Receivables
22.54 19.35 16.91 15.21 13.99 21.73 20.97 20.97 —
Average Payables
5.22 3.58 4.97 8.64 7.67 3.61 2.07 2.12 2.12
Average Inventory
7.76 9.15 14.31 19.12 14.88 9.38 7.74 3.54 3.54
Average Assets
119.30 133.89 188.32 293.86 382.85 231.20 27.14 27.14 —
Average Common Equity
78.06 93.90 138.09 228.76 330.30 121.53 (107.94) (107.94) —

Fold the line items

Columns are period end dates